StocksMediumUpdated×4•Originally published 3 November 2026•Updated 3 November 2026•
1 min read
Pfizer Beats Q3 Estimates and Raises Full-Year Revenue Guidance
Key Facts
1In August, Pfizer raised the midpoint of its 2026 revenue range by $500 million to $60.5–$62.5 billion and kept adjusted earnings per share at $2.80–$3.00.
2Second-quarter revenue was $15.034 billion, up 3% overall and 1% operationally year over year.
3The company cut its 2026 revenue forecast for COVID products to about $4 billion from about $5 billion previously.
4The third-quarter results event is scheduled for Nov. 3, 2026, at 10:00 a.m. Eastern time.
Pfizer reported third-quarter 2026 adjusted earnings of $0.87 per share, beating analyst estimates. The company stated in its results release that quarterly revenue reached $16.58 billion, reflecting a strong performance that prompted management to revise its full-year outlook.
Pfizer raised its full-year 2026 revenue guidance to a range of $62 billion to $64 billion, up from the previous range of $60.5 billion to $62.5 billion issued in August. This growth follows a second quarter where the company reported $15.034 billion in revenue and had previously increased its non-COVID product estimates by $1.5 billion while cutting COVID product expectations to approximately $4 billion.